TY - JOUR
T1 - Reduced-intensity conditioning is effective for hematopoietic stem cell transplantation in young pediatric patients with Diamond–Blackfan anemia
AU - Koyamaishi, Shun
AU - Kamio, Takuya
AU - Kobayashi, Akie
AU - Sato, Tomohiko
AU - Kudo, Ko
AU - Sasaki, Shinya
AU - Kanezaki, Rika
AU - Hasegawa, Daiichiro
AU - Muramatsu, Hideki
AU - Takahashi, Yoshiyuki
AU - Sasahara, Yoji
AU - Hiramatsu, Hidefumi
AU - Kakuda, Harumi
AU - Tanaka, Miyuki
AU - Ishimura, Masataka
AU - Nishi, Masanori
AU - Ishiguro, Akira
AU - Yabe, Hiromasa
AU - Sarashina, Takeo
AU - Yamamoto, Masaki
AU - Yuza, Yuki
AU - Hyakuna, Nobuyuki
AU - Yoshida, Kenichi
AU - Kanno, Hitoshi
AU - Ohga, Shouichi
AU - Ohara, Akira
AU - Kojima, Seiji
AU - Miyano, Satoru
AU - Ogawa, Seishi
AU - Toki, Tsutomu
AU - Terui, Kiminori
AU - Ito, Etsuro
N1 - Funding Information:
Fig. 1 Kaplan-Meier analysis of outcomes in Diamond-Blackfan anemia patients who underwent hematopoitetic stem cell transplantation. Probability of overall survival (OS) (a, c) and failure-free survival (FFS) (b, d) of patients with Diamond–Blackfan anemia after hematopoietic stem cell transplantation (HSCT). Graft failure and Acknowledgements We thank all medical and co-medical staffs who participated in the treatment of DBA patients in Japan. This work was supported by a research grant from the Ministry of Health, Labor and Welfare of Japan (Research on Measures for Intractable Diseases) (19FC1005) and by Grant-in-aids for scientific research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (KAKENHI: 17K10093, 18K07868), from the Japan Agency for Medical Research and Development (AMED) (JP19cm0106501 and 15H05909), from the Japan Society for the Promotion of Science (JSPS) (JP19H05656), and from the Ministry of Education, Culture, Sports, Science and Technology (hp160219).
Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2021/5
Y1 - 2021/5
N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for the hematologic manifestations of Diamond–Blackfan anemia (DBA). However, data regarding the optimal conditioning regimen for DBA patients are limited. We retrospectively compared the outcomes of DBA patients who underwent HSCT using either myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC) regimens. The patients belonged to a cohort treated at our hospitals between 2000 and 2018. HSCT was performed in 27 of 165 patients (16.4%). The median age at the time of HSCT was 3.6 years. Stem cell sources included bone marrow for 25 patients (HLA-matched sibling donors, n = 5; HLA-mismatched related donors, n = 2; HLA-matched/mismatched unrelated donors, n = 18) or cord blood for 2 patients. MAC or RIC regimens were used in 12 and 15 patients, respectively. Engraftment was successful in all 27 patients who underwent HSCT. Three patients who underwent HSCT using MAC regimens developed sinusoidal obstruction syndrome. The 3-year overall survival (OS) and failure-free survival rates (FFS) post-transplantations were 95.2% and 88.4%, respectively, with no significant differences between MAC and RIC regimens. Our data suggest that HSCTs using RIC regimens are effective and obtain engraftment with excellent OS and FFS for young DBA patients.
AB - Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for the hematologic manifestations of Diamond–Blackfan anemia (DBA). However, data regarding the optimal conditioning regimen for DBA patients are limited. We retrospectively compared the outcomes of DBA patients who underwent HSCT using either myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC) regimens. The patients belonged to a cohort treated at our hospitals between 2000 and 2018. HSCT was performed in 27 of 165 patients (16.4%). The median age at the time of HSCT was 3.6 years. Stem cell sources included bone marrow for 25 patients (HLA-matched sibling donors, n = 5; HLA-mismatched related donors, n = 2; HLA-matched/mismatched unrelated donors, n = 18) or cord blood for 2 patients. MAC or RIC regimens were used in 12 and 15 patients, respectively. Engraftment was successful in all 27 patients who underwent HSCT. Three patients who underwent HSCT using MAC regimens developed sinusoidal obstruction syndrome. The 3-year overall survival (OS) and failure-free survival rates (FFS) post-transplantations were 95.2% and 88.4%, respectively, with no significant differences between MAC and RIC regimens. Our data suggest that HSCTs using RIC regimens are effective and obtain engraftment with excellent OS and FFS for young DBA patients.
UR - http://www.scopus.com/inward/record.url?scp=85091031116&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091031116&partnerID=8YFLogxK
U2 - 10.1038/s41409-020-01056-1
DO - 10.1038/s41409-020-01056-1
M3 - Article
C2 - 32948829
AN - SCOPUS:85091031116
SN - 0268-3369
VL - 56
SP - 1013
EP - 1020
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 5
ER -